Q2 2019 Pharmaceuticals Partnerships, Licensing, Investments and M&A Deals and Trends - ResearchAndMarkets.com

DUBLIN--()--The "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2019" report has been added to ResearchAndMarkets.com's offering.

The Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2019 report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q2 2019.

The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the five quarters.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q2 2019

2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q2 2019

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q2 2019

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q2 2019

2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2019

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type

3.1 Pharmaceuticals & Healthcare, Global, M&A, Q2 2019

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q2 2019

3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q2 2019

3.5 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q2 2019

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2019

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2019

4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q2 2018 - Q2 2019

4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2019

4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2018 - Q2 2019

4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q2 2018 - Q2 2019

4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q2 2018 - Q2 2019

4.8 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2018 - Q2 2019

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q2 2019

5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q2 2019

5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2018 - Q2 2019

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q2 2018 - Q2 2019

5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q2 2018 - Q2 2019

5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2018 - Q2 2019

5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2018 - Q2 2019

5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q2 2018 - Q2 2019

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area

6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q2 2019

6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q2 2019

6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q2 2019

6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q2 2019

6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q2 2019

6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q2 2019

6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q2 2019

6.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q2 2019

6.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q2 2019

6.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q2 2019

7 Deal Summary by Geography

8 Pharmaceuticals & Healthcare, Global, Top Advisors

8.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q2 2018 - Q2 2019

8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q2 2018 - Q2 2019

For more information about this report visit https://www.researchandmarkets.com/r/rfj278

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900